Advertisement
Screener

Protara Therapeutics, Inc. (TARA) Graph

TARA Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Revenue (m); Research and development $16.95M; Operating expenses $23.32M; Income tax (m).
  • 2026-03-31: Revenue (m); Research and development $13.56M; Operating expenses $19.63M; Income tax (m).
  • 2025-12-31: Revenue (m); Research and development $13.12M*; Operating expenses $19.08M*; Income tax (m).
  • 2025-09-30: Revenue (m); Research and development $9.59M; Operating expenses $14.76M; Income tax (m).

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$16.95M$23.32M(m)-$21.67M
2026-03-31(m)$13.56M$19.63M(m)-$17.78M
2025-12-31(m)$13.12M*$19.08M*(m)-$17.27M*
2025-09-30(m)$9.59M$14.76M(m)-$13.26M
2025-06-30(m)$10.77M$16.59M(m)-$14.96M
2025-03-31(m)$9.15M$14.12M(m)-$11.91M
2024-09-30(m)$8.07M$12.33M(m)-$11.22M
2024-06-30(m)$6.39M$10.66M(m)-$9.51M
2024-03-31(m)$7.75M$11.85M(m)-$11.10M
2023-09-30(m)$6.22M$10.70M(m)-$9.86M
2023-06-30(m)$7.25M$12.14M(m)-$11.29M
2023-03-31(m)$5.14M$9.73M(m)-$9.04M
2022-09-30(m)$3.47M$7.97M(m)-$7.69M
2022-06-30(m)$3.08M$8.71M(m)-$8.54M
2022-03-31(m)$5.27M$10.87M(m)-$10.76M
2021-09-30(m)$4.09M$10.83M(m)-$10.78M
2021-06-30(m)$5.89M$12.79M(m)-$12.78M
2021-03-31(m)$7.04M$13.58M(m)-$13.46M
2020-09-30(m)$2.80M$8.06M(m)-$7.97M
2020-06-30(m)$2.47M$7.27M(m)-$7.14M
2020-03-31(m)$3.06M$10.16M(m)-$10.06M
2019-09-30(m)$1.10M$2.35M(m)-$2.35M
2019-06-30(m)$986.72K$1.43M(m)-$1.43M
2019-03-31(m)$1.08M$1.53M$0.00-$1.53M
2018-12-31(m)(m)$5.38M(m)(m)
2018-09-30(m)$2.35M$4.62M(m)-$4.51M
2018-06-30(m)$2.76M$5.00M(m)-$4.88M
2018-03-31(m)$4.07M$6.37M$0.00-$6.08M
2017-12-31(m)(m)$5.59M(m)(m)
2017-09-30(m)$10.34M$12.31M(m)-$12.31M
2017-06-30(m)$3.89M$5.99M(m)-$5.61M
2017-03-31(m)$4.25M$6.48M$0.00-$6.50M
2016-12-31(m)(m)$6.87M(m)(m)
2016-09-30(m)$4.84M$7.17M(m)-$7.11M
2016-06-30(m)$5.24M$7.85M(m)-$7.91M
2016-03-31(m)$4.35M$6.82M$0.00-$6.55M
2015-12-31(m)(m)$6.19M(m)(m)
2015-09-30(m)$3.08M$5.08M$0.00-$5.38M
2015-06-30(m)$3.09M$4.98M$0.00-$5.07M
2015-03-31(m)$2.63M$4.62M$0.00-$4.58M
2014-12-31(m)(m)$3.27M(m)$7.23M
2014-09-30$2.95M$1.77M$2.81M$0.00-$5.18M
2014-06-30(m)$1.60M$2.51M$0.00-$2.56M
2014-03-31(m)$1.19M$1.93M$0.00-$2.83M
2013-12-31(m)(m)$1.79M(m)-$2.40M
2013-09-30(m)$971.00K$1.91M$0.00-$2.10M
2013-06-30(m)(m)$1.55M(m)-$1.55M
2013-03-31(m)(m)$1.87M(m)-$1.86M

Revenue and expense 6 month

Period endResearch and developmentOperating expensesIncome taxNet income
2026-06-30$30.52M$42.95M(m)-$39.45M
2025-06-30$19.92M$30.71M(m)-$26.87M
2024-06-30$14.13M$22.51M(m)-$20.61M
2023-06-30$12.39M$21.87M(m)-$20.34M
2022-06-30$8.35M$19.58M(m)-$19.29M
2021-06-30$12.93M$26.37M(m)-$26.25M
2020-06-30$5.53M$17.43M(m)-$17.20M
2019-06-30$2.06M$2.96M$0.00-$2.96M
2018-06-30$6.83M$11.37M$0.00-$10.96M
2017-06-30$8.14M$12.47M$0.00-$12.11M
2016-06-30$9.59M$14.67M$0.00-$14.46M
2015-06-30$5.72M$9.60M$0.00-$9.65M
2014-06-30$2.79M$4.44M$0.00-$5.39M

Revenue and expense 9 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-09-30(m)$29.51M$45.47M(m)-$40.13M
2024-09-30(m)$22.20M$34.84M(m)-$31.83M
2023-09-30(m)$18.61M$32.57M(m)-$30.20M
2022-09-30(m)$11.82M$27.55M(m)-$26.98M
2021-09-30(m)$17.02M$37.20M(m)-$37.02M
2020-09-30(m)$8.33M$25.49M(m)-$25.17M
2019-09-30(m)$3.16M$5.31M$0.00-$5.31M
2018-09-30(m)$9.19M$15.99M$0.00-$15.47M
2017-09-30(m)$18.47M$24.77M$0.00-$24.41M
2016-09-30(m)$14.43M$21.84M$0.00-$21.56M
2015-09-30(m)$8.80M$14.68M$0.00-$15.04M
2014-09-30$2.95M$4.56M$7.25M$0.00-$10.57M
2013-09-30(m)$2.97M$5.33M$0.00-$5.51M

Revenue and expense 12 month

Period endRevenueResearch and developmentOperating expensesIncome taxNet income
2025-12-31(m)$42.63M$64.55M(m)-$57.40M
2024-12-31(m)$31.70M$49.15M(m)-$44.60M
2023-12-31(m)$24.99M$43.61M(m)-$40.40M
2022-12-31(m)$16.81M$67.06M(m)-$65.95M
2021-12-31(m)$21.09M$47.49M(m)-$47.25M
2020-12-31(m)$11.98M$34.44M(m)-$33.98M
2019-12-31(m)$3.88M$7.83M(m)-$7.83M
2018-12-31(m)$11.85M$21.37M(m)-$20.73M
2017-12-31(m)$21.69M$30.36M(m)-$29.96M
2016-12-31(m)$18.87M$28.70M(m)-$28.53M
2015-12-31(m)$12.38M$20.87M(m)-$21.38M
2014-12-31$2.95M$6.43M$10.53M-$110.00K-$3.34M
2013-12-31(m)$3.99M$7.12M$92.00K-$7.91M
2012-12-31(m)$5.91M$8.00M-$140.00K-$7.97M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Compass Therapeutics, Inc. (CMPX)United States$0.204B-5.35
Alpha Cognition Inc. (ACOG)$0.185B-6.77
Alector, Inc. (ALEC)United States$0.213B-1.90
Coherus Oncology, Inc. (CHRS)United States$0.182B-1.63
ANAVEX LIFE SCIENCES CORP. (AVXL)United States$0.218B-18.37
Protalix BioTherapeutics, Inc. (PLX)$0.221B9.87
PRECISION BIOSCIENCES INC (DTIL)United States$0.175B-3.95
Voyager Therapeutics, Inc. (VYGR)United States$0.173B-1.99
Acumen Pharmaceuticals, Inc. (ABOS)United States$0.162B-1.83
Outlook Therapeutics, Inc. (OTLK)United States$0.162B-4.90